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Background
Eosinophils play a key role in allergic diseases such as
bronchial asthma and atopic dermatitis. A prominent fea-
ture of these diseases is the accumulation of eosinophils
in inflamed tissue induced by several chemoattractants
like prostaglandin (PG) D2 or eotaxins. After the discov-
ery of the endocannabinoid system and investigation of
several endogenous and synthetic ligands, evidence has
accumulated that cannabinoids, especially CB2 receptor
ligands, may play a major role in mediating inflammatory
responses. Elevated levels of 2-arachidonoylglycerol (2-
AG; a CB1/CB2 agonist) were found in tissues of mouse
models of allergic inflammation, suggesting a possible
involvement in leukocyte recruitment.
Methods
Blood was sampled from healthy volunteers, erythrocytes
were removed by dextran sedimentation and polymorpho-
nuclear leukocytes were obtained via Histopaque gradi-
ents. For all assays eosinophils were further purified by
negative magnetic isolation. Shape change was recorded
immediately after stimulation on a FACSCalibur flow cyt-
ometer. For chemotaxis assays an AP48 microBoyden
chamber was used and migration time was 1h at 37°C.
Intracellular Ca2+ levels were analyzed by flow cytometry
after treating eosinophils with Fluo-3-AM for 60min at
room temperature.
Results
We found that CB2 receptor agonists like the endocanna-
binoid 2-AG or the synthetic selective agonist JWH-133
significantly increased eosinophil responses in shape
change assays induced by PGD2 or eotaxin-1. The
observed effects could be abolished by pretreatment with
the selective CB2 receptor antagonists SR144528 or
AM630. As cytoskeletal changes are required for firm
arrest and leukocyte diapedesis, transmigration assays
were conducted subsequently, confirming the shape
change data as eosinophil migration induced by PGD2 was
increased by pretreatment with JWH-133. Calcium flux
assays showed Ca2+ mobilization induced by JWH-133
and the tendency to increase PGD2-induced Ca
2+ release.
Conclusions
We could show that JWH-133 can influence human eosi-
nophil activation/migration via activation of CB2 receptors
as chemoattractant effects were significantly modulated,
suggesting a possible pro-inflammatory role in allergic
inflammation which may further lead to cannabinoid-
based treatment options in allergic inflammatory diseases.
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